Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Akebia/Otsuka's Vadadustat Hits Primary Target in Multinational PIII
May 8, 2020
- Takeda to Maintain Partial Voluntary Ban on Sales Reps Activities in Japan amid Coronavirus Woes
May 8, 2020
- Kyowa Kirin’s Q1 Sales Tick Up as North America Revenue Counters Japan Dip
May 7, 2020
- Fujifilm to Carry Out Process Development, Manufacturing of COVID-19 Treatment for Anti-COVID-19 Initiative
May 7, 2020
- Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
- Sanofi Warns of QT Prolongation for Plaquenil after FDA/EMA Flag Risks in COVID-19
May 1, 2020
- Taisho Licenses HIF-PH Inhibitor to US Biotech for Age-Related Diseases
May 1, 2020
- Mitsubishi Tanabe Drops Seasonal Flu Vaccine Project in US, Canadian Plan Intact
April 30, 2020
- Wakamoto, Rohto Forge Comprehensive Biz Tie-Up
April 30, 2020
- Shionogi’s Novel Antibiotic Cefiderocol Approved in Europe
April 30, 2020
- Astellas, Harvard Seal 3-Year Research Alliance Pact
April 30, 2020
- Chugai Plans May Enrollment Start for Actemra COVID-19 Trial, Aims for Approval by Year-End
April 30, 2020
- Mitsuka to Bow Out from Mitsubishi Tanabe Board
April 30, 2020
- Bayer Japan Ethical Drug Sales Grow 4.2% in 2019
April 30, 2020
- Sanofi Japan to Ensure Drug Supplies, Employees’ Safety at the Same Time in COVID-19 Crisis: Chief
April 30, 2020
- AZ to Divest 4 Off-Patent Drugs to Taiyo Pharma
April 30, 2020
- Lilly’s 3 Tadalafil Products Transferred to Nippon Shinyaku
April 30, 2020
- Sumitomo Dainippon Ups FY2019 Guidance on Brisk North America, Japan Biz
April 30, 2020
- Takeda’s Mobocertinib Bags FDA Breakthrough Therapy Status for EGFR Exon 20 Mutant NSCLC
April 30, 2020
- Sumitomo Dainippon, Nihon Generic Pulling Some Metformin Products over Carcinogen Risks
April 28, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…